<!-- rapid-acting.html -->
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Long-Acting + GLP-1 RA</title>
  <style> 
    /* Global Styles - Apply to the entire site */
body {
  font-family: 'Arial', sans-serif;
  background-color: #f4f6f9;
  margin: 0;
  padding: 0;
  text-align: center;
  color: #333;
}

.content {
  width: 80%;
  max-width: 1200px;
  margin: 40px auto;
  background-color: #ffffff;
  padding: 30px;
  border-radius: 10px;
  box-shadow: 0 4px 8px rgba(0, 0, 0, 0.1);
}

h1 {
  font-size: 2rem;
  color: #2c3e50;
  margin-bottom: 20px;
}

p {
  font-size: 1.1rem;
  color: #34495e;
  line-height: 1.6;
  margin-bottom: 30px;
}

/* Table Styles - Global (For Main Page & Sub-Pages) */
.star-measures-table {
  width: 100%;
  border-collapse: collapse;
  margin-top: 30px;
  background-color: #ffffff;
  border-radius: 8px;
  overflow: hidden;
  box-shadow: 0 4px 8px rgba(0, 0, 0, 0.1);
}

.star-measures-table thead {
  background-color: #006f92;  /* Rich blue for header */
  color: white;
  text-align: center;
  font-weight: bold;
}

.star-measures-table th, .star-measures-table td {
  padding: 8px 5px;
  font-size: 1.1rem;
  text-align: center;
  border: 2px solid #ddd;
  
}

.star-measures-table tbody tr:nth-child(even) {
  background-color: #f4f8fb;  /* Soft light blue-gray for even rows */
}

.star-measures-table tbody tr:nth-child(odd) {
  background-color: #ffffff;  /* White background for odd rows */
}

.star-measures-table tbody tr:hover {
  background-color: #e0f7fa;  /* Light cyan hover effect */
  transition: background-color 0.3s ease;
}

.star-measures-table td {
  color: #555;
    line-height: 1.6;
}

.star-measures-table th {
  font-size: 1.2rem;
  text-transform: uppercase;
  letter-spacing: 1px;
  background-color: #192655;
  color: white;
  padding: 14px 20px;
}
      
      .clinical {
          font-size: 1.1rem;
  color: #34495e;
  line-height: 1.6;
  
    text-align: left;
      }

/* Dropdown Styles */
.dropdown-container {
  display: flex;
  justify-content: center;
  gap: 20px;
  margin-top: 20px;
}

select {
  padding: 12px 18px;
  font-size: 1rem;
  border-radius: 5px;
  border: 1px solid #ddd;
  background-color: #f9f9f9;
  color: #555;
  width: 200px;
  cursor: pointer;
}

select:focus {
  border-color: #007bff;
  outline: none;
}

select option {
  padding: 10px;
}

/* Responsive Design */
@media (max-width: 768px) {
  .content {
    width: 90%;
    padding: 20px;
  }

  .star-measures-table th, .star-measures-table td {
    padding: 10px 12px;
  }

  select {
    width: 150px;
  }
}
    </style>
</head>
    
<body>
  <div class="category-page">
    <h2>Long-Acting + GLP-1 RA</h2>
    <p>This page focuses on all Long-Acting + GLP-1 RA Insulin medications and you can look up their information easily</p>
    <table class="star-measures-table">
      <thead>
        <tr>
          <th>Medication Name</th>
          <th>Duration</th>
          <th>Information</th>
        </tr>
      </thead>
        
      <tbody>
        <tr>
          <td><strong>Xultophy [Pen] </strong><br>
              Generic: Insulin degludec + liraglutide (analog)
            </td>
            
          <td>Up to 42 hours (degludec) </td>
            <td>
                <div class="clinical">
                <strong>Indications:</strong>
                    Type 2, not for Type 1
                    <br>
                    <strong>MOA:</strong>
                    Combine MOA of Insulin degludec and MOA of GLP-1 agonist
                    <br>
                    <strong>Dosing (Adult):</strong>
                    10 units subcutaneously daily<strong>(Patients naive to basal insulin or a GLP-1 agonist)</strong>/ 16 units subcutaneously daily <strong>(Patients currently on basal insulin or a GLP-1 agonist)</strong>
                    <br>
                    <strong>Side Effects:</strong>
                    pain and redness at the injection site, low blood sugar
                    <br>
                    <strong>Monitoring:</strong>
                    Check blood sugar levels, check A1C every 3 - 6 months
               
                  
                </div>       
            </td>
        </tr>
          
        <tr>
          <td><strong>Soliqua [SoloStar]</strong> <br>
            Generic: Insulin glargine + lixisenatide (analog)
            </td>
          <td> 24 - 30 hours (glargine)</td>
            <td>
            <div class="clinical">
                <strong>Indications:</strong>
                    Type 2, not for Type 1
                    <br>
                    <strong>MOA:</strong>
                    Combine MOA of Insulin glargine and MOA of GLP-1 agonist
                    <br>
                    <strong>Dosing (Adult):</strong>
                    15 units subcutaneously daily<strong>(Patients naive to basal insulin or a GLP-1 agonist)</strong>/ 30 units subcutaneously daily <strong>(Patients currently on basal insulin or a GLP-1 agonist)</strong>
                    <br>
                    <strong>Side Effects:</strong>
                    pain and redness at the injection site, low blood sugar
                    <br>
                    <strong>Monitoring:</strong>
                    Check blood sugar levels, check A1C every 3 - 6 months
               
                  
                </div>
            </td>
        </tr>
          
   
      </tbody>
    </table>
  </div>
    
    <footer style="text-align: center; margin-top: 20px;">
        <a href="index.html">Home</a>
        <p>References: Pyrls and Lexidrug <br>
        &copy; 2024 Insulin Products. All rights reserved</p>
    </footer>
    
</body>
</html>
